(Reuters) – AstraZeneca said on Tuesday it had submitted a request with U.S. health regulators to grant emergency use authorisation for a new treatment to prevent COVID-19.
The British drugmaker had said in August that the treatment, an antibody therapy called AZD7442, had reduced the risk of people developing any COVID-19 symptoms by 77% in a late-stage trial.
(Reporting by Sachin Ravikumar in Bengaluru; Editing by Sriraj Kalluvila)
